A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Conditions
Cancer · Melanoma Stage III · Melanoma Stage IV · Cutaneous Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCLA Health, Los Angeles, California, United States
Mission Dermatology Center, Rancho Santa Margarita, California, United States
BRCR Global, Weston, Florida, United States
IU Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Henry Ford Cancer Institute, Detroit, Michigan, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Morristown Medical Center / Atlantic Health System, Morristown, New Jersey, United States
Contact: Study coordinator (Salome Geene, RN, CRC, BSN) · salome.geene@atlantichealth.org · 973-971-6373Weill Cornell Medicine-New York-Presbyterian Hospital, New York, New York, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Renovatio Clinical - El Paso, El Paso, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Renovatio Clinical - The Woodlands, The Woodlands, Texas, United States
Study leads
David Chien, MD
Study Director
Senior Vice President of Clinical Development